HC Wainwright Analysts Lift Earnings Estimates for GALT

Key Points

• HC Wainwright raised its Galectin Therapeutics earnings estimates, forecasting Q3 2026 EPS of $(0.05), up from $(0.10), while maintaining a Buy rating and an $11 price target.
• Galectin reported Q2 earnings of $(0.14) per share, missing the consensus estimate of $(0.09). Overall analyst sentiment remains Hold, with a consensus target price of $11.00.
• GALT shares opened at $3.51, well below the 52-week high of $7.13. Insiders sold 90,162 shares worth about $438,000 over the past 90 days, while institutional investors own 11.68% of the company.

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Stock analysts at HC Wainwright boosted their Q3 2026 earnings estimates for shares of Galectin Therapeutics in a research note issued on Friday, August 14th. HC Wainwright analyst M. Keller now anticipates that the company will earn ($0.05) per share for the quarter, up from their prior forecast of ($0.10). HC Wainwright has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for Galectin Therapeutics' Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.30) EPS and FY2027 earnings at ($0.23) EPS.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.05).

A number of other research firms have also recently issued reports on GALT. Zacks Research upgraded Galectin Therapeutics from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 11th. Weiss Ratings upgraded Galectin Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, June 18th. Finally, Wall Street Zen upgraded shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 13th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $11.00.

Galectin Therapeutics Stock Performance

Shares of NASDAQ GALT opened at $3.51 on Tuesday. The business's 50 day moving average price is $3.63 and its 200-day moving average price is $3.00. Galectin Therapeutics has a fifty-two week low of $2.03 and a fifty-two week high of $7.13. The company has a market cap of $231.17 million, a price-to-earnings ratio of -8.16 and a beta of 0.41.

Insider Buying and Selling at Galectin Therapeutics

In related news, insider Khurram Jamil sold 47,467 shares of the firm's stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $5.04, for a total transaction of $239,233.68. Following the sale, the insider directly owned 2,037 shares of the company's stock, valued at $10,266.48. This trade represents a 95.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Harold H. Shlevin sold 22,268 shares of the business's stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $5.04, for a total value of $112,230.72. Following the completion of the transaction, the director directly owned 6,500 shares of the company's stock, valued at $32,760. The trade was a 77.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 90,162 shares of company stock worth $438,464 over the last ninety days. Corporate insiders own 52.60% of the company's stock.

Institutional Trading of Galectin Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Argyle Capital Partners LLC acquired a new position in shares of Galectin Therapeutics in the second quarter worth about $62,000. Bank of New York Mellon Corp acquired a new stake in shares of Galectin Therapeutics during the 2nd quarter valued at about $491,000. Bank of America Corp DE increased its stake in shares of Galectin Therapeutics by 114.9% in the 1st quarter. Bank of America Corp DE now owns 53,862 shares of the company's stock valued at $150,000 after purchasing an additional 28,799 shares in the last quarter. Vivaldi Capital Management LP raised its holdings in Galectin Therapeutics by 26.7% in the 1st quarter. Vivaldi Capital Management LP now owns 258,584 shares of the company's stock worth $721,000 after purchasing an additional 54,514 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in Galectin Therapeutics during the first quarter worth approximately $413,000. Institutional investors and hedge funds own 11.68% of the company's stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company's lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source